Neurophth
PrivateLast Round
Series D
Aug 25, 2026
Est. Valuation
$700M
Total Funding Raised
$240.67M
Momentum
Top 50%
of companies Caplight tracks
Company Overview
Neurophth operates in Healthcare & Life Sciences and is based in Wuhan. Its latest recorded funding round was a Series D round in August 2026.
Neurophth is a biotechnology company that develops gene therapies for the treatment of ophthalmological disorders.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Clinical Trials, Precision Medicine, Drug Discovery
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Neurophth Comparables
Compare Neurophth with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| SparingVision | 84% | |
| HuidaGene Therapeutics | 84% | |
| Beacon Therapeutics | 83% |
For institutional investors. Book with your work email.
Neurophth Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series D | Aug 25, 2026 | ||||
| Series C Extension | Aug 11, 2023 | ||||
| Series C | Nov 23, 2021 | ||||
| Series B | Feb 9, 2021 | ||||
| Series A | Apr 9, 2020 | ||||
Angel | Aug 1, 2018 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
Neurophth Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Huaxin Investment China InnoVision Capital | Series B |
| Oriza Holdings | Series B |
| 招银国际金融有限公司 | Series C |
| Northern Light Venture Capital | Angel, Series B, Series A |
| InnoVision Capital | Series B |
| InnoStar Capital | Series A |
| Shanghai International Group | Series B |
For institutional investors. Book with your work email.
Market signals
Structured signals derived from secondary market and firmographic data.
- Aug 25, 2026
Completed a Series D funding round.
- Aug 11, 2023
$95M round led by Guangzhou Financial Holdings Fund Management.
For institutional investors. Book with your work email.
Neurophth Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Neurophth's valuation, stock price, and market status.
Is Neurophth a public or private company?
Neurophth is a private company.
What is the current stock price of Neurophth?
Neurophth is a private company, so its shares have no public market price. Caplight tracks Neurophth's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Neurophth worth (valuation)?
Neurophth's valuation is estimated at $700.0M based on funding round data.
Can I buy Neurophth stock?
Neurophth shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Neurophth's last funding round?
Neurophth's most recent funding round was Series D on August 25, 2026.
Who are the main investors in Neurophth?
Key investors in Neurophth include Huaxin Investment China InnoVision Capital, InnoVision Capital, InnoStar Capital, Shanghai International Group, Shanghai Guofang Private Equity Fund Management.
Will Neurophth IPO soon?
No public IPO plans have been announced for Neurophth.
How can I track Neurophth secondary market activity?
Caplight tracks bids, offers, and trades in Neurophth's shares on secondary markets.